← Oncology Approval Tracker

FDA DECISION ·

Brukinsa

zanubrutinib · BeiGene

FDA approvalNew or expanded indicationWaldenström macroglobulinemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with Waldenström macroglobulinemia.

LAMPGEN ANALYSIS

Why it matters

The label adds an oral BTK inhibitor option for this lymphoplasmacytic lymphoma.

What research teams should watch

Capture baseline IgM and disease-related symptoms alongside hematologic response and tolerability.

PRIMARY RECORDS

Sources